Scarica l'app Stockscreener
1.03
0.98%
0.01
Precedente Chiudi:
$1.02
Aprire:
$1.05
Volume 24 ore:
130.06K
Relative Volume:
0.73
Capitalizzazione di mercato:
$32.32M
Reddito:
$90,000
Utile/perdita netta:
$-23.47M
Rapporto P/E:
-1.3693
EPS:
-0.7522
Flusso di cassa netto:
$-22.98M
1 W Prestazione:
-0.96%
1M Prestazione:
-11.97%
6M Prestazione:
-35.22%
1 anno Prestazione:
-29.45%
Intervallo 1D:
$1.02
$1.11
Intervallo di 1 settimana:
$0.98
$1.11
Portata 52W:
$0.952
$1.89
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Nome
Actinium Pharmaceuticals Inc
Settore
Industria
Telefono
646-767-3870
Indirizzo
275 Madison Avenue, 7th Floor, New York, NY
Compare ATNM vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.03 | 32.32M | 90,000 | -23.47M | -22.98M | -0.7522 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-07 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-02-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-08-25 | Iniziato | B. Riley Securities | Buy |
| 2020-11-05 | Iniziato | Alliance Global Partners | Buy |
| 2017-12-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | Ripresa | ROTH Capital | Buy |
| 2017-09-14 | Iniziato | Maxim Group | Buy |
| 2016-08-25 | Iniziato | ROTH Capital | Buy |
| 2016-02-29 | Iniziato | H.C. Wainwright | Buy |
| 2015-10-15 | Iniziato | FBR Capital | Outperform |
| 2014-10-01 | Iniziato | MLV & Co | Buy |
| 2014-07-22 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Actinium Pharmaceuticals Inc Borsa (ATNM) Ultime notizie
Actinium Pharmaceuticals Inc (ATNM) Institutional Confidence - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Actinium Pharmaceuticals Submits NYSE American Compliance Plan After Equity Deficiency Notice - Minichart
Actinium Submits NYSE Compliance Plan to Restore Listing - TipRanks
Actinium (NYSE: ATNM) details plan to regain NYSE American listing - Stock Titan
Actinium Pharmaceuticals Inc (ATNM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Actinium Pharmaceuticals Inc - TradingKey
ATNM Should I Buy - Intellectia AI
Actinium Pharmaceuticals presents expanded ATNM-400 results in NSCLC and prostate cancer - Traders Union
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC - BioWorld News
Actinium presents preclinical data on ATNM-400 for lung cancer - Investing.com UK
Actinium Pharmaceuticals (ATNM) Reveals Promising Preclinical Data for NSCLC Treatment - GuruFocus
Actinium presents preclinical data on ATNM-400 for lung cancer By Investing.com - Investing.com Australia
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer - PR Newswire
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models - PR Newswire
Actinium Pharmaceuticals (ATNM) Appoints New Chief Medical Officer - GuruFocus
Actinium Pharmaceuticals (ATNM) Unveils Key Radiochemistry Findi - GuruFocus
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development - PR Newswire
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates - PR Newswire
Actinium Pharmaceuticals Presents ATNM-400 Program Updates at SNMMI 2026 and Addresses NYSE American Listing Compliance Notice - Minichart
Actinium Pharmaceuticals Advances with Canadian Patent Allowances for ATNM - GuruFocus
Actinium Highlights New ATNM-400 Data Amid Listing Pressure - TipRanks
Actinium Pharmaceuticals, Inc. (ATNM) announced that two patent applications related to its Actimab-a and Iomab-Act projects have been granted by the Canadian Intellectual Property Office. - Bitget
Actinium Pharmaceuticalsreceives two Canadian patent allowances for Actimab-A and Iomab-Act programs - marketscreener.com
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs - PR Newswire
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice – Company AnnouncementFT.com - Financial Times
Actinium Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Actinium Pharmaceuticals (NYSE: ATNM) faces NYSE American equity shortfall and listing risk - Stock Titan
ATNM Stock Price, Quote & Chart | ACTINIUM PHARMACEUTICALS INC (NYSEARCA:ATNM) - ChartMill
Actinium Pharmaceuticals (ATNM): Modest Gain Above Support as Biotech Stock Holds Key LevelRegression Channel - The Legal Advocate
Actinium Pharmaceuticals (ATNM) Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Advances ContinueRevenue Beat Analysis - The Legal Advocate
Actinium Pharmaceuticals (ATNM) Q1 2026 Earnings: Narrower Loss Beats Expectations as Development Pipeline AdvancesEarnings Surprise Report - newsline.com
Actinium (ATNM) Delivers Q1 2026 Beat — EPS $-0.18 vs $-0.24 ExpectedMost Discussed Stocks - Newser
Actinium (ATNM) Falls -2.34% — Watching $1.19 Support 2026-05-15Viral Trade Signals - newser.com
TradingKey - TradingKey
MSN Money - MSN
Actinium: Q1 Earnings Snapshot - 10TV
[10-Q] Actinium Pharmaceuticals, Inc. Quarterly Earnings Report - Stock Titan
Actinium Pharmaceuticals Inc. (ATNM) Stock Price | Live Quotes & Charts | AMEX - StocksToTrade
Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization - Barchart.com
Actinium presents preclinical data on AML drug at AACR meeting By Investing.com - Investing.com India
Actinium Pharmaceuticals (ATNM) Unveils Promising Preclinical Fi - GuruFocus
Actinium Pharmaceuticals (ATNM) Presents Promising Data on Actim - GuruFocus
Actinium presents preclinical data on AML drug at AACR meeting - Investing.com
Actinium Pharmaceuticals presents preclinical data for ATNM-400 - Investing.com
Actinium Pharmaceuticals presents preclinical data for ATNM-400 By Investing.com - Investing.com South Africa
Actinium Pharmaceuticals Inc Azioni (ATNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):